CN100534976C - S-1-(4-ethoxybenzyl)-3-azapentane-1,5 diamine preparation method - Google Patents

S-1-(4-ethoxybenzyl)-3-azapentane-1,5 diamine preparation method Download PDF

Info

Publication number
CN100534976C
CN100534976C CNB2007100193790A CN200710019379A CN100534976C CN 100534976 C CN100534976 C CN 100534976C CN B2007100193790 A CNB2007100193790 A CN B2007100193790A CN 200710019379 A CN200710019379 A CN 200710019379A CN 100534976 C CN100534976 C CN 100534976C
Authority
CN
China
Prior art keywords
ethyl
amino
reaction
alkyl ester
amido protecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CNB2007100193790A
Other languages
Chinese (zh)
Other versions
CN101007775A (en
Inventor
何拥军
谢敏浩
罗世能
刘娅灵
邹霈
王洪勇
吴军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Jiangsu Institute of Nuclear Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Institute of Nuclear Medicine filed Critical Jiangsu Institute of Nuclear Medicine
Priority to CNB2007100193790A priority Critical patent/CN100534976C/en
Publication of CN101007775A publication Critical patent/CN101007775A/en
Application granted granted Critical
Publication of CN100534976C publication Critical patent/CN100534976C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The invention discloses a making method of S-1-(4-ethoxy benzyl)-3-aza pantane-1, 5 diamine in the organic synthetic technical domain, which comprises the following steps: 1reacting L-tyrosine alkyl ester protected by amino and ethyl iodide catalyzed by anhydrous carbonate alkali to produce L-tyrosine alkyl ester protected by O-ethyl-amino; 2. reacting L-tyrosine alkyl ester protected by O-ethyl-amino and anhydrous ethanediamine to do ester exchange to produce O-ethyl-L-tyrosinamide protected by N-(2-amino ethyl)-amino; 3. stripping protecting group of amino through trifluoroacetic acid; 4. using aluminium lithium hydroxide to reduce; obtaining the product. The invention reduces technical difficulty with mild reacting condition, which can prepare key intermediate of Gadoxetic acid disodium (Gd-EOB-DTPA).

Description

The preparation method of a kind of S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5 diamines
Technical field
The present invention relates to the preparation method of S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5 diamines, belong to technical field of organic synthesis.It is liver specificity magnetic resonance contrast agent Gadoxetic acid disodium (Gadoxetic aciddisodium, key intermediate Gd-EOB-DTPA).
Background technology
Nuclear magnetic resonance (MRI) technology has a wide range of applications at biology and medical field, has become a kind of common medical diagnosis means.In order to strengthen the contrast gradient and the sharpness of image, often select in the clinical MRI to use suitable contrast medium, about 30% MRI need use contrast medium.The important research direction of magnetic resonance contrast agent is the contrast medium that development has organ, tissue target tropism in the world, can make contrast medium be enriched in specific organ or tissue, improves the radiography effect, reduces dosage, reduces toxicity.Gadoxetic acid disodium (Gadoxetic aciddisodium) is by the paramagnetism gadolinium ion and lipophilic ethoxy benzyl diethylenetriamine pentaacetic acid part chelating is formed, normal liver cell optionally absorbs the Gd-EOB-DTPA molecule, obviously improve the T1 relaxation efficient of tissue, help detecting of liver lesion, can improve the recall rate of little liver neoplasm especially, thereby help the early diagnosis and therapy of liver neoplasm.
S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5 diamines is the key intermediate of Gadoxetic acid disodium. U.S. Pat 5,695, and 739 and document Inorg.Chem 1999,38,1134~1144 have reported synthetic route.With N-benzene methoxycarbonyl-L-L-Tyrosine methyl ester is raw material; Anhydrous potassium carbonate exists down and the iodoethane reaction obtained O-ethyl-N-benzene methoxycarbonyl-L-L-Tyrosine methyl ester in 20 hours; quadrol with 20 times of molar weights carries out transesterify generation N-(2-amino-ethyl)-N-benzene methoxycarbonyl-O-ethyl-L-tyramine amide again; make catalyzer with Pd/C then; 15 normal atmosphere are down with hydrogen reaction deaminize protecting group; obtain S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5 diamines with the diborane reducing amide at last.Synthetic route is as follows:
Figure C20071001937900031
In this synthetic route, the 3rd step deaminize protecting group is made catalyzer with Pd/C, and 15 normal atmosphere are used hydrogen reaction down, and first equipment requirements is higher, and second uses the security requirement of hydrogen also high.Diborane is used in the reduction of the 4th step acid amides, and diborane is a flammable and explosive substance, and transportation, storage require all very high, and the reaction times reaches 32 hours, causes the equipment work efficiency low, and diborane toxicity is big, and is dangerous high.Therefore document method needs to improve.
Summary of the invention
The invention provides the preparation method of a kind of S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5 diamines, the objective of the invention is to design a kind of suitable suitability for industrialized production, operational path is new preparation method reasonably.
Technical scheme of the present invention: reaction scheme is as follows:
Figure C20071001937900041
1. the L-tyrosine alkyl ester with amido protecting is a raw material, under the effect of Carbon Dioxide an alkali metal salt, carry out ethylation reaction and generate O-ethyl-amido protecting-L-tyrosine alkyl ester with iodoethane, the L-tyrosine alkyl ester of amido protecting and iodoethane molar ratio are for waiting mole, temperature of reaction is 20~25 ℃, reaction times is 20 hours, aftertreatment with ethyl acetate extraction after evaporate to dryness, do not need purifying directly to enter the next step; 2.O-carrying out transesterification reaction, ethyl-amido protecting-L-tyrosine alkyl ester and anhydrous ethylenediamine generate N-(2-amino-ethyl)-amido protecting-O-ethyl-L-tyramine amide, O-ethyl-amido protecting-L-tyrosine alkyl ester and anhydrous ethylenediamine molar ratio are 1: 20, temperature of reaction is 50 ℃, and the reaction times is 20 hours; 3. remove amino protecting group with trifluoroacetic acid, the trifluoroacetic acid that adds and the mol ratio of N-(2-amino-ethyl)-amido protecting-O-ethyl-L-tyramine amide are 1.0~3.0: 1, temperature of reaction is 0~30 ℃, reaction times is 0.5~5 hour, and product can directly enter next step reduction reaction behind the concentrating under reduced pressure evaporate to dryness; 4. use lithium aluminum hydride as reductive agent, the reducing amide base makes S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5 diamines, the lithium aluminum hydride that adds and the mol ratio of N-(2-amino-ethyl)-O-ethyl-L-tyramine amide are 3.0~4.0: 1, temperature of reaction is 50 ℃, and the reaction times is 2~5 hours, substitutes diborane with lithium aluminum hydride, shorten the reaction times, aftertreatment is simple.
The amino protecting group of the L-tyrosine alkyl ester of the amido protecting that the present invention adopts is any one in tertbutyloxycarbonyl (Boc) or the benzene methoxycarbonyl (Cbz).
The alkyl of the L-tyrosine alkyl ester of the amido protecting that the present invention adopts is any one in methyl or ethyl or propyl group or the sec.-propyl.
The Carbon Dioxide an alkali metal salt that the present invention adopts is any in Anhydrous potassium carbonate or the anhydrous sodium carbonate.
Beneficial effect of the present invention: the S-1-that provides (4-ethoxy benzyl)-3-aza-pentane-1, the preparation method of 5 diamines is on the prior art basis, adopted a kind of safe and reliable working method, avoided high pressure, hydrogen, diborane etc. to equipment, the high condition of security requirement, has reaction temperature and controlled, reaction times is short, easy to operate, safe, the yield height, advantages such as recycled solvent, the suitability for industrialized production of suitable S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5 diamines.
Embodiment
Synthesizing of embodiment 1 O-ethyl-N-boc-L-tyrosine ethyl ester:
Add N-boc-L-tyrosine ethyl ester (24.8g in the 500mL three-necked flask, 0.08mol) and 180mLDMF in, add 22.0g Anhydrous potassium carbonate and iodoethane (7mL after the stirring and dissolving successively, 0.08mol), kept 25 ℃ of stirring at room 20 hours, the aftertreatment ethyl acetate extraction, evaporated under reduced pressure gets O-ethyl-N-boc-L-tyrosine ethyl ester (25.2g, 0.075mol), need not purifying and directly supply next step (embodiment 2) reaction, ethyl acetate reclaims to be used.Molar yield is 93.8% (the HPLC detection level is 96.2%).
Synthesizing of embodiment 2 N-(2-amino-ethyl)-N-boc-O-ethyl-L-tyramine amide:
O-ethyl-N-boc-L-tyrosine ethyl ester (25.2g that back (embodiment 1) is obtained, 0.075mol) be dissolved in 100mL methyl alcohol, slowly drop to and be added with anhydrous ethylenediamine (90g in 500mL three-necked flask 1.5mol), dropwises back 50 ℃ and continue to stir 20 hours.Evaporated under reduced pressure adds the 60mL ethyl acetate in the residue, leave standstill after the heating for dissolving, the white solid that collection is separated out, 50 ℃ dry N-(2-amino-ethyl)-N-boc-O-ethyl-L-tyramine amide (20g, 0.054mol), molar yield is 72%, and ethyl acetate reclaims to be used.mp94~96℃,MS:367。
Synthesizing of embodiment 3 N-(2-amino-ethyl)-O-ethyl-L-tyramine amide:
Add N-(2-amino-ethyl)-N-boc-O-ethyl-L-tyramine amide (32g in the 500mL three-necked flask, 0.087mol) and the 400mL methylene dichloride, add trifluoroacetic acid (22.8g after the stirring and dissolving, 0.2mol) stirring at room 1 hour, the concentrating under reduced pressure evaporate to dryness get N-(2-amino-ethyl)-O-ethyl-L-tyrosyl (18g, 0.072mol), molar yield is 83%, mp94~96 ℃ (highly finished product), MS:251.
Synthesizing of embodiment 4 S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5 diamines:
In being housed, the 1000mL three-necked flask of dropping funnel and reflux adds LiAlH 4(15g, 0.4mol) and the 250mL tetrahydrofuran (THF), (25g 0.1mol) is dissolved in the 150mL tetrahydrofuran (THF), slowly drops in the flask, keeps that reaction solution is little to boil, 50 ℃ of reactions 3 hours with N-(2-amino-ethyl)-O-ethyl-L-tyramine amide.Add the postcooling reaction solution to room temperature.Filter, filter cake tetrahydrofuran (THF) washed twice, merging filtrate, evaporated under reduced pressure, must white solid (22.5g, 0.095mol), molar yield is 95%, mp170~172 ℃, MS:237 is product S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5 diamines.

Claims (3)

1, the preparation method of a kind of S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5 diamines is characterized in that branch four step carries out:
(1) the L-tyrosine alkyl ester of amido protecting and iodoethane are made reaction generation O-ethyl-amido protecting L-tyrosine alkyl ester under the catalyzer at the Carbon Dioxide an alkali metal salt, the L-tyrosine alkyl ester of amido protecting and iodoethane molar ratio are for waiting mole, temperature of reaction is 20~25 ℃, reaction times is 20 hours, aftertreatment with ethyl acetate extraction after evaporate to dryness, enter the next step;
(2) O-ethyl-amido protecting L-tyrosine alkyl ester and anhydrous ethylenediamine carry out transesterification reaction generation N-(2-amino-ethyl)-amido protecting-O-ethyl-L-tyramine amide, O-ethyl-amido protecting-L-tyrosine alkyl ester and anhydrous ethylenediamine molar ratio are 1: 20, temperature of reaction is 50 ℃, and the reaction times is 20 hours;
(3) with trifluoroacetic acid deaminize protecting group, the trifluoroacetic acid that adds and the mol ratio of N-(2-amino-ethyl)-amido protecting-O-ethyl-L-tyramine amide are 1.0~3.0: 1, temperature of reaction is 0~30 ℃, reaction times is 0.5~5 hour, enters next step reduction reaction behind the concentrating under reduced pressure evaporate to dryness;
(4) make S-1-(4-ethoxy benzyl)-3-aza-pentane-1 with lithium aluminium hydride reduction, 5 diamines, the lithium aluminum hydride that adds and the mol ratio of N-(2-amino-ethyl)-O-ethyl-L-tyramine amide are 3.0~4.0: 1, and temperature of reaction is 50 ℃, the reaction times is 2~5 hours;
The amino protecting group of the L-tyrosine alkyl ester of described amido protecting is a tertbutyloxycarbonyl.
2, the preparation method of S-1-according to claim 1 (4-ethoxy benzyl)-3-aza-pentane-1,5 diamines, the alkyl that it is characterized in that the L-tyrosine alkyl ester of described amido protecting is any one in methyl or ethyl or propyl group or the sec.-propyl.
3, the preparation method of S-1-according to claim 1 (4-ethoxy benzyl)-3-aza-pentane-1,5 diamines is characterized in that described Carbon Dioxide an alkali metal salt is any one in Anhydrous potassium carbonate or the anhydrous sodium carbonate.
CNB2007100193790A 2007-01-16 2007-01-16 S-1-(4-ethoxybenzyl)-3-azapentane-1,5 diamine preparation method Active CN100534976C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2007100193790A CN100534976C (en) 2007-01-16 2007-01-16 S-1-(4-ethoxybenzyl)-3-azapentane-1,5 diamine preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2007100193790A CN100534976C (en) 2007-01-16 2007-01-16 S-1-(4-ethoxybenzyl)-3-azapentane-1,5 diamine preparation method

Publications (2)

Publication Number Publication Date
CN101007775A CN101007775A (en) 2007-08-01
CN100534976C true CN100534976C (en) 2009-09-02

Family

ID=38696478

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2007100193790A Active CN100534976C (en) 2007-01-16 2007-01-16 S-1-(4-ethoxybenzyl)-3-azapentane-1,5 diamine preparation method

Country Status (1)

Country Link
CN (1) CN100534976C (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102188928A (en) * 2010-03-08 2011-09-21 中国科学院成都有机化学有限公司 Fluorocarbon cationic gemini and hybridized gemini surfactants and synthesis method thereof
CN103896788B (en) * 2012-12-27 2016-03-02 齐鲁制药有限公司 A kind of preparation method of S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5-diamines tri hydrochloride
CN103864630B (en) * 2014-03-21 2015-07-01 福州大学 Synthesis method of (S)-1-(4-ethyoxyl benzyl)-3-azapentane-1,5-diamine trihydrochloride
EP3464237B1 (en) * 2016-05-30 2023-12-20 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of gadolinium complex of (4s)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9- triazaundecanedioic acid disodium (gadoxetate disodium)
KR20180050091A (en) * 2016-11-04 2018-05-14 에스티팜 주식회사 A method for preparation of (S)-N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrocholoride
KR101935636B1 (en) 2016-11-04 2019-01-07 에스티팜 주식회사 A method for preparation of (S)-N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrocholoride

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Synthesis and Physicochemical Characterizationof a NewGadolinium Chelate:TheLiver-specific Magnetic ResonanceImaging Contrast AgentGd-EOB-DTPA. H. Schmitt-Willich,ET AL.Inorg. Chem.,Vol.38 No.6. 1999
Synthesis and Physicochemical Characterizationof a NewGadolinium Chelate:TheLiver-specific Magnetic ResonanceImaging Contrast AgentGd-EOB-DTPA. H. Schmitt-Willich,ET AL.Inorg. Chem.,Vol.38 No.6. 1999 *

Also Published As

Publication number Publication date
CN101007775A (en) 2007-08-01

Similar Documents

Publication Publication Date Title
CN100534976C (en) S-1-(4-ethoxybenzyl)-3-azapentane-1,5 diamine preparation method
US20100022791A1 (en) Organometallic complexes as hydrogen storage materials and a method of preparing the same
BRPI0719367B1 (en) PROCESS FOR THE PREPARATION OF NEBIVOLOL, ITS INTERMEDIARIES AND USES
CN103896788B (en) A kind of preparation method of S-1-(4-ethoxy benzyl)-3-aza-pentane-1,5-diamines tri hydrochloride
WO2020220963A1 (en) Amphiphilic molecule containing o-nitrobenzyl ester-based photodegradable group, and synthesis method therefor
CN103242177A (en) Preparation method of 2,5-diaminophenethyl alcohol sulfate
CN111393329A (en) Preparation method of ritonavir and lopinavir intermediate
WO2023039940A1 (en) Method for preparing n,n,n-tripivaloyl-1,3,5-triaminobenzene
CN101704788B (en) Improved preparation process of 2-Butyl-1,3-diazapira[4,4]nonane-1-en-4-one
CN104761461A (en) Preparation method of novel gadoxetate disodium intermediate
CN102367228A (en) Method for synthesizing agomelatine
CN101239932B (en) Preparation of 3,5-di(2-cyano-isopropyl)-toluene
Li et al. Platinum nanoparticles as recyclable heterogeneous catalyst for selective methylation of amines and imines with formic acid: Indirect utilization of CO2
CN103113397A (en) Preparation method of amino borane
CN106083693A (en) The N phthalyl synthesis technique to (dihydroxy ethyl) amino L phenylalanine ethyl ester
CN102010386B (en) Method for preparing trimetazidine hydrochloride
CN114181117A (en) Preparation method of peramivir intermediate
CN102584739A (en) Carboxyl benzyl replaced nitrogen dioxide crown ether derivative and synthesizing method thereof
CN101914051B (en) Synthesis method of 3-phenyl pyrroline derivatives with optical isomerism purity
CA2194480A1 (en) Amino acid-derived diaminopropanols
CN104672099A (en) New preparation method of gadoxetic acid disodium intermediate
CN114573496B (en) Preparation method of 4-chloroindole-3-acetic acid
CN110590744A (en) Micromolecule PET imaging agent of targeted chemokine receptor CXCR4
CN114805231B (en) Synthesis method of p-NH2-Bn-NOTA
CN113248415B (en) Preparation method of ABT-737 key intermediate and preparation method of ABT-737

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: JIANGSU CHIA-TAI TIANQING PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: JIANGSU INSTITUTE OF NUCLEAR MEDICINE

Effective date: 20100612

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 214063 NO.20, QIANRONG ROAD, WUXI CITY, JIANGSU PROVINCE TO: 222006 NO.8, JULONG NORTH ROAD, XINPU DISTRICT, LIANYUNGANG CITY, JIANGSU PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20100612

Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No.

Patentee after: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd.

Address before: 214063 Jiangsu city of Wuxi province Qian Rong Lu No. 20

Patentee before: Jiangsu Prov. Inst. of Atomic Medicine

C56 Change in the name or address of the patentee

Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No.

Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No.

Patentee before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd.